Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration
Fig 1
Delayed oseltamivir plus sirolimus treatment still attenuated pH1N1 virus-induced mortality.
BALB/c mice were infected with pH1N1. Survival rate (A) and weight change ratio (B) following treatment with PBS, sirolimus (2 hpi), sirolimus (2 dpi), oseltamivir (2 hpi), oseltamivir (2 hpi) + sirolimus (2 hpi), or oseltamivir (2 hpi) + sirolimus (2 dpi). Survival rate (C) and weight change ratio (D) after treatment with PBS, oseltamivir (2 dpi), sirolimus (2 dpi), or oseltamivir (2 dpi) + sirolimus (2 dpi). Data are representative of two independent experiments (n = 8 for each group). In Fig 1A and 1B, ** and *** represent p < 0.01 and 0.001, respectively, when compared to the PBS-treated group. In Fig 1C, ** represent p < 0.01 when oseltamivir (2 dpi) + sirolimus (2 dpi) group compared to the oseltamivir group; ‡ represent p < 0.01 when oseltamivir (2 dpi) + sirolimus (2 dpi) group compared to the PBS group.